Selected article for: "critically ill patient and intensive care unit"
Author: Brown, Anne Rain Tanner; Horng, Michelle; Shigle, Terri Lynn
Title: Considerations for Medications Commonly Utilized in the Oncology Population in the Intensive Care Unit
  • Cord-id: 1u55sl98
  • Document date: 2019_7_9
    • ID: 1u55sl98
    Snippet: An increasing number of oncologic patients are presenting to the intensive care unit with complications from both their chronic disease states and cancer therapies due to improved survival rates. The management of these patients is complex due to immunosuppression (from the malignancy and/or treatment), metabolic complications, and diverse medication regimens with the potential for significant drug-drug interactions and overlapping adverse effects. This chapter will provide clinicians with an ov
    Document: An increasing number of oncologic patients are presenting to the intensive care unit with complications from both their chronic disease states and cancer therapies due to improved survival rates. The management of these patients is complex due to immunosuppression (from the malignancy and/or treatment), metabolic complications, and diverse medication regimens with the potential for significant drug-drug interactions and overlapping adverse effects. This chapter will provide clinicians with an overview of non-chemotherapy medications frequently encountered in the critically ill oncologic patient, with a focus on practical considerations.

    Search related documents:
    Co phrase search for related documents
    • abdominal liver and active bleeding: 1
    • abdominal liver and acute toxicity: 1, 2
    • abdominal pain and absence presence: 1, 2, 3, 4, 5, 6
    • abdominal pain and absolute neutrophil count: 1
    • abdominal pain and active bleeding: 1, 2
    • abdominal pain and acute aki kidney injury: 1, 2, 3, 4, 5, 6
    • abdominal pain and acute toxicity: 1, 2
    • abdominal pain and additional risk factor: 1
    • absence presence and absolute neutrophil count: 1
    • absence presence and acute aki kidney injury: 1, 2, 3
    • absence presence and acute toxicity: 1
    • absence presence and additional information: 1, 2, 3
    • absence presence and additional risk factor: 1
    • absence presence and adjunctive treatment: 1
    • absolute neutrophil count and acute aki kidney injury: 1
    • acute aki kidney injury and additional information: 1, 2, 3
    • acute aki kidney injury and additional risk factor: 1, 2, 3